Therabel Pharmaceuticals will use Itamar's Endopat device in a clinical trial of its treatment for hardening of the arteries.
Itamar Medical Ltd. (TASE:ITMR) has won a $400,000 contract to supply its Endopat non-invasive monitor of endothelial function to Therabel Pharmaceuticals Ltd.
Therabel will use the Endopat for a multi-center Phase IV clinical trial to test the effectiveness of its Molsidomine drug for treating endothelial dysfunction (hardening of the arteries).
Itamar Medical's share price rose 0.1% by midday to NIS 2.21, giving a market cap of NIS 295 million.
Published by Globes [online], Israel business news - www.globes-online.com - on April 6, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011